An Imbalanced OPG/TRAIL Ratio is Associated to Severe Acute Myocardial Infarction

Overview

Journal Atherosclerosis

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2009 Dec 18

PMID 20015493

Citations 29

Authors

Paola Secchiero

Federica Corallini

Antonio Paolo Beltrami

Claudio Ceconi

Vincenzo Bonasia

Antonio Di Chiara

Roberto Ferrari

Giorgio Zauli

Affiliations

Soon will be listed here.

Abstract

Background: This study was designed to evaluate the biological significance of simultaneous changes in the circulating levels of osteoprotegerin (OPG) and TNF-related apoptosis inducing ligand (TRAIL) in patients with coronary artery disease (CAD), and, in particular, with acute myocardial infarction (AMI).

Methods: Total levels of OPG and TRAIL were measured by ELISA in patients with AMI (n=113), unstable angina (UA, n=21) and healthy controls (n=120).

Results: Since OPG was elevated during the acute phase (first 12-24-48h) after AMI and in patients with UA with respect to healthy controls, while TRAIL was decreased in acute AMI patients, CAD patients were characterized by an increased OPG/TRAIL ratio. Moreover, the OPG/TRAIL ratio was significantly (p<0.05) higher in the acute AMI patients who developed heart failure (HF) than in those who did not develop HF in the follow-up.

Conclusions: An impaired OPG/TRAIL ratio after AMI is related to a higher risk of HF.

Citing Articles

Vascular Cytokines and Atherosclerosis: Differential Serum Levels of TRAIL, IL-18, and OPG in Obstructive Coronary Artery Disease.

Bate K, Genetzakis E, Vescovi J, Gray M, Celermajer D, McGuire H Biomolecules. 2024; 14(9).

PMID: 39334884 PMC: 11430378. DOI: 10.3390/biom14091119.

Osteoprotegerin Is Essential for the Development of Endothelial Dysfunction Induced by Angiotensin II in Mice.

Dutka M, Garczorz W, Kosowska A, Buczek E, Godek P, Wojakowski W Int J Mol Sci. 2024; 25(12).

PMID: 38928140 PMC: 11203749. DOI: 10.3390/ijms25126434.

TRAIL and its receptors in cardiac diseases.

Grisanti L Front Physiol. 2023; 14:1256852.

PMID: 37621762 PMC: 10445540. DOI: 10.3389/fphys.2023.1256852.

Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial.

Ma T, Zhao J, Yan Y, Liu J, Zang J, Zhang Y Front Cardiovasc Med. 2023; 10:1178153.

PMID: 37388640 PMC: 10300416. DOI: 10.3389/fcvm.2023.1178153.

Tumor Necrosis Factor Family Members and Myocardial Ischemia-Reperfusion Injury: State of the Art and Therapeutic Implications.

Galeone A, Grano M, Brunetti G Int J Mol Sci. 2023; 24(5).

PMID: 36902036 PMC: 10003149. DOI: 10.3390/ijms24054606.